Regulation of nausea and vomiting by cannabinoids

Linda A Parker, Erin M Rock, Cheryl L Limebeer, Linda A Parker, Erin M Rock, Cheryl L Limebeer

Abstract

Considerable evidence demonstrates that manipulation of the endocannabinoid system regulates nausea and vomiting in humans and other animals. The anti-emetic effect of cannabinoids has been shown across a wide variety of animals that are capable of vomiting in response to a toxic challenge. CB(1) agonism suppresses vomiting, which is reversed by CB(1) antagonism, and CB(1) inverse agonism promotes vomiting. Recently, evidence from animal experiments suggests that cannabinoids may be especially useful in treating the more difficult to control symptoms of nausea and anticipatory nausea in chemotherapy patients, which are less well controlled by the currently available conventional pharmaceutical agents. Although rats and mice are incapable of vomiting, they display a distinctive conditioned gaping response when re-exposed to cues (flavours or contexts) paired with a nauseating treatment. Cannabinoid agonists (Δ(9) -THC, HU-210) and the fatty acid amide hydrolase (FAAH) inhibitor, URB-597, suppress conditioned gaping reactions (nausea) in rats as they suppress vomiting in emetic species. Inverse agonists, but not neutral antagonists, of the CB(1) receptor promote nausea, and at subthreshold doses potentiate nausea produced by other toxins (LiCl). The primary non-psychoactive compound in cannabis, cannabidiol (CBD), also suppresses nausea and vomiting within a limited dose range. The anti-nausea/anti-emetic effects of CBD may be mediated by indirect activation of somatodendritic 5-HT(1A) receptors in the dorsal raphe nucleus; activation of these autoreceptors reduces the release of 5-HT in terminal forebrain regions. Preclinical research indicates that cannabinioids, including CBD, may be effective clinically for treating both nausea and vomiting produced by chemotherapy or other therapeutic treatments.

© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

References

    1. Biol Pharm Bull. 1998 Mar;21(3):224-6
    1. Lancet Oncol. 2005 Jan;6(1):35-42
    1. Neuropsychopharmacology. 2008 Mar;33(4):946-55
    1. Eur J Pharmacol. 1998 Jul 10;352(2-3):143-9
    1. Radiology. 1984 Feb;150(2):598-9
    1. Pharmacol Biochem Behav. 1999 Jan;62(1):75-80
    1. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):239-49
    1. Neuroreport. 2002 Apr 16;13(5):567-70
    1. Behav Neurosci. 2002 Apr;116(2):321-33
    1. J Pharmacol Exp Ther. 2005 Apr;313(1):352-8
    1. Med Oncol Tumor Pharmacother. 1986;3(1):39-42
    1. Psychopharmacology (Berl). 2007 Feb;190(2):135-43
    1. Cancer. 2003 Jun 1;97(11):2880-6
    1. Pharmacol Biochem Behav. 1989 Jul;33(3):627-31
    1. Jpn J Pharmacol. 1991 Jan;55(1):107-13
    1. Eur J Pharmacol. 1997 Dec 11;340(2-3):217-20
    1. Neuropsychopharmacology. 2001 Feb;24(2):198-203
    1. Eur J Neurosci. 2007 May;25(9):2773-82
    1. Pharmacol Biochem Behav. 1994 Oct;49(2):385-91
    1. Eur J Cancer Clin Oncol. 1988 Apr;24(4):685-9
    1. Nat Chem Biol. 2009 Jan;5(1):37-44
    1. Eur J Pharmacol. 1996 Oct 3;312(3):273-9
    1. Neuropharmacology. 1993 Aug;32(8):799-806
    1. Brain Res. 1978 Mar 24;143(2):263-79
    1. Br J Pharmacol. 2002 Nov;137(5):589-96
    1. J Clin Invest. 2010 Aug;120(8):2953-66
    1. Br J Cancer. 1994 May;69(5):957-60
    1. Integr Physiol Behav Sci. 1993 Apr-Jun;28(2):177-81
    1. Physiol Behav. 2006 Jan 30;87(1):66-71
    1. Indian J Physiol Pharmacol. 2002 Oct;46(4):463-7
    1. Pharmacol Biochem Behav. 2003 Jul;75(4):777-87
    1. Eur J Cancer. 2001 Dec;37(18):2398-404
    1. Psychopharmacology (Berl). 2003 Mar;166(2):156-62
    1. Br J Pharmacol. 2010 Oct;161(3):629-42
    1. Integr Physiol Behav Sci. 2003 Apr-Jun;38(2):133-45
    1. Psychopharmacology (Berl). 2004 Jul;174(2):254-9
    1. J Support Oncol. 2007 May;5(5 Suppl 3):1-9
    1. Gastroenterology. 2001 Oct;121(4):767-74
    1. Neuroscience. 2002;109(3):451-60
    1. Psychopharmacology (Berl). 1978 Jan 31;56(1):21-5
    1. Eur J Pharmacol. 2001 Oct 26;430(1):49-58
    1. Physiol Behav. 2009 Apr 20;97(1):121-4
    1. Prostaglandins Leukot Essent Fatty Acids. 1995 Jul;53(1):1-11
    1. Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1243-55
    1. Neurosci Lett. 1998 Oct 16;255(2):63-6
    1. Science. 2005 Oct 14;310(5746):329-32
    1. Life Sci. 1995;56(23-24):2097-102
    1. Pharmacol Biochem Behav. 1995 Nov;52(3):571-5
    1. Eur J Pharmacol. 1998 Oct 16;359(1):49-54
    1. Neurochem Res. 2005 Aug;30(8):1037-43
    1. BMJ. 2001 Jul 7;323(7303):16-21
    1. Neuroreport. 1999 Dec 16;10(18):3769-72
    1. Neurosci Biobehav Rev. 1995 Spring;19(1):143-57
    1. Br J Pharmacol. 2009 Feb;156(3):397-411
    1. Psychopharmacology (Berl). 2004 Jan;171(2):156-61
    1. Gut. 2001 Jun;48(6):859-67
    1. Trends Pharmacol Sci. 2001 Nov;22(11):565-72
    1. Eur J Cancer. 2005 Jan;41(2):199-205
    1. J Pharmacol Exp Ther. 2002 Jan;300(1):34-42
    1. Eur J Cancer. 2003 May;39(8):1074-80
    1. Pharmacol Biochem Behav. 1990 Oct;37(2):283-7
    1. Anesthesiology. 2001 May;94(5):882-7
    1. Psychopharmacology (Berl). 2003 Mar;166(2):120-6
    1. Eur J Pharmacol. 2003 Jun 20;471(2):129-34
    1. Physiol Behav. 2006 Jul 30;88(4-5):398-403
    1. J Clin Pharmacol. 1981 Aug-Sep;21(S1):30S-37S
    1. Curr Med Res Opin. 2007 Mar;23(3):533-43
    1. Ann Oncol. 2003 Feb;14(2):291-7
    1. Neuroreport. 2001 Mar 26;12(4):749-51
    1. Eur J Pharmacol. 2002 May 10;442(3):273-8
    1. Br J Pharmacol. 2005 Dec;146(7):913-5
    1. J Exp Psychol Anim Behav Process. 2002 Jan;28(1):75-82
    1. Jpn J Pharmacol. 1988 Oct;48(2):303-6
    1. Am J Physiol Regul Integr Comp Physiol. 2007 Dec;293(6):R2185-93
    1. Ann Intern Med. 1983 Jul;99(1):106-14
    1. Pharmacol Biochem Behav. 2006 Dec;85(4):820-6
    1. Pharmacol Biochem Behav. 1991 Dec;40(4):983-6
    1. Learn Behav. 2003 May;31(2):165-72
    1. Psychopharmacology (Berl). 2005 Jul;180(2):286-93
    1. Pharmacol Biochem Behav. 1983 Apr;18(4):629-35
    1. Eur J Biochem. 2004 May;271(10):1827-34
    1. J Exp Psychol Anim Behav Process. 2000 Oct;26(4):371-84
    1. Science. 1974 Sep 6;185(4154):824-31
    1. Life Sci. 1987 Jul 27;41(4):513-8
    1. Behav Brain Res. 2008 Feb 11;187(1):33-40
    1. Behav Neurosci. 2004 Dec;118(6):1391-9
    1. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):150-6
    1. Psychosom Med. 1980 Jan;42(1):33-6
    1. Eur J Pharmacol. 2004 Mar 19;488(1-3):201-12
    1. J Clin Pharmacol. 2002 Nov;42(S1):11S-19S
    1. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G566-76
    1. Br J Cancer. 1997;76(8):1055-61
    1. Pharmacol Rev. 2002 Jun;54(2):161-202
    1. Behav Neurosci. 1992 Oct;106(5):820-36
    1. Br J Pharmacol. 2010 Sep;161(2):336-49
    1. JAMA. 2006 Feb 15;295(7):761-75
    1. Jpn J Pharmacol. 1994 Feb;64(2):109-14
    1. Cancer. 2002 Jun 1;94(11):3032-41
    1. Pharmacol Rev. 1953 Jun;5(2):193-230
    1. Physiol Behav. 1992 Nov;52(5):895-9
    1. Cell Mol Life Sci. 2003 Mar;60(3):607-16
    1. Intern Med J. 2002 Aug;32(8):401-7
    1. Brain Res. 1991 Nov 29;565(2):231-6
    1. Br J Pharmacol. 1996 Nov;119(5):931-6
    1. Neuropharmacology. 2005 Sep;49(4):502-13
    1. Behav Brain Res. 2009 Jan 3;196(1):30-6
    1. Chem Biol. 2009 Jul 31;16(7):744-53
    1. J Pharmacol Exp Ther. 2010 May;333(2):547-54
    1. J Comp Physiol Psychol. 1972 Oct;81(1):21-6
    1. Pharmacol Biochem Behav. 2010 Nov;97(1):179-84
    1. Eur J Pharmacol. 2008 Oct 31;596(1-3):98-101
    1. J Neurophysiol. 1995 Feb;73(2):907-10
    1. Psychopharmacology (Berl). 1982;78(3):277-81
    1. Can J Exp Psychol. 2008 Sep;62(3):198-209
    1. Neuroscience. 2006;139(4):1405-15
    1. Behav Neurosci. 1986 Aug;100(4):544-55
    1. Biochem Biophys Res Commun. 1999 Aug 19;262(1):275-84
    1. Science. 1976 Mar 26;191(4233):1273-5
    1. Synapse. 1987;1(5):470-80
    1. Auton Neurosci. 2006 Apr 30;125(1-2):100-15
    1. Psychopharmacology (Berl). 2008 Feb;196(3):389-95
    1. Am J Surg. 2006 Jun;191(6):767-72
    1. Health Qual Life Outcomes. 2003 Sep 17;1:46
    1. Pharmacol Biochem Behav. 2009 Jan;91(3):367-73
    1. Br J Pharmacol. 2000 Jul;130(6):1247-54
    1. Br J Pharmacol. 1996 May;118(2):209-14
    1. Am J Med. 2001 Dec 3;111 Suppl 8A:106S-112S
    1. Eur J Pharmacol. 1989 Oct 4;169(1):159-65
    1. J Pain Symptom Manage. 2010 Feb;39(2):167-79
    1. Br J Pharmacol. 1986 Jul;88(3):497-9
    1. Eur J Pharmacol. 1996 Jul 4;307(3):305-13
    1. Psychopharmacology (Berl). 1997 Sep;133(1):51-4
    1. J Exp Psychol Anim Behav Process. 1998 Oct;24(4):483-91
    1. Neuropharmacology. 1986 Aug;25(8):959-61

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel